Therefore new studies are being conducted, such as GASTRODOC Regimen (docetaxel, oxaliplatin and capecitabine), where Monti et al. veryfied whether four cycles of NAC were superior to perioperative CTH for locally advanced GC [63], providing higher progression-free survival (PFS) and nodal response rates (from 22% of cN0 to 34% of ypN0) in experimental group. Here, CTH is linked to gastric cancer.